Publicado 4 números por año
ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448
Indexed in
Histone Acetyltransferases in Cancer: Guardians or Hazards?
SINOPSIS
Histone acetyltransferases (HATs) catalyzing N-epsilon-lysine or N-alpha-terminal acetylation on histone and non-histone substrates are important epigenetic regulators controlling gene expression and chromatin structure. Deregulation of these enzymes by genetic or epigenetic alterations accompanied by defects in gene transcription have been implicated in oncogenesis. Therefore, these enzymes are considered promising therapeutic targets, offering new horizons for epigenetic cancer therapy. However, recent observations suggest that these enzymes function as both oncogenes and tumor suppressors. In this review, we present the current evidence demonstrating that individual HATs can either prevent cancer cell proliferation or drive malignant transformation depending on the molecular context and cancer type. We therefore advocate that future therapeutic interventions targeted toward these enzymes should carefully consider the fact that HATs commonly have a two-sided role in carcinogenesis.
-
Hua Hui, Zhang Hongying, Kong Qingbin, Jiang Yangfu, Mechanisms for estrogen receptor expression in human cancer, Experimental Hematology & Oncology, 7, 1, 2018. Crossref
-
Demetriadou Christina, Pavlou Demetria, Mpekris Fotios, Achilleos Charis, Stylianopoulos Triantafyllos, Zaravinos Apostolos, Papageorgis Panagiotis, Kirmizis Antonis, NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression, Cell Death & Disease, 10, 3, 2019. Crossref
-
Jia Yanshu, Wen Xiaoyue, Gong Yufeng, Wang Xuefeng, Current scenario of indole derivatives with potential anti-drug-resistant cancer activity, European Journal of Medicinal Chemistry, 200, 2020. Crossref
-
Collier Christopher D., Getty Patrick J., Greenfield Edward M., Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma, in Current Advances in the Science of Osteosarcoma, 1258, 2020. Crossref
-
Demetriadou Christina, Koufaris Costas, Kirmizis Antonis, Histone N-alpha terminal modifications: genome regulation at the tip of the tail, Epigenetics & Chromatin, 13, 1, 2020. Crossref
-
Zhang Jun, Lu Xiaopeng, MoghaddamKohi Sara, Shi Lei, Xu Xingzhi, Zhu Wei-Guo, Histone lysine modifying enzymes and their critical roles in DNA double-strand break repair, DNA Repair, 107, 2021. Crossref
-
O’Garro Chenise, Igbineweka Loveth, Ali Zonaira, Mezei Mihaly, Mujtaba Shiraz, The Biological Significance of Targeting Acetylation-Mediated Gene Regulation for Designing New Mechanistic Tools and Potential Therapeutics, Biomolecules, 11, 3, 2021. Crossref
-
Xiong Ying, Zhang Mingming, Li Yingxia, Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors, Current Medicinal Chemistry, 27, 33, 2020. Crossref
-
Shanmugam Muthu K., Dharmarajan Arunasalam, Warrier Sudha, Bishayee Anupam, Kumar Alan Prem, Sethi Gautam, Ahn Kwang Seok, Role of histone acetyltransferase inhibitors in cancer therapy, in Apoptosis in Health and Disease - Part A, 125, 2021. Crossref
-
Liu Yu’e, Chen Chao, Wang Xinye, Sun Yihong, Zhang Jin, Chen Juxiang, Shi Yufeng, An Epigenetic Role of Mitochondria in Cancer, Cells, 11, 16, 2022. Crossref
-
Ganai Shabir Ahmad, Epigenetic Regulator Enzymes and Their Implications in Distinct Malignancies, in Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy, 2020. Crossref
-
Arakelyan Jemma, Rusanov Daniil A., Chang Meng Rui, Asaturova Aleksandra V., Kireeva Galina S., Alshehri Mana, Ang Wee Han, Babak Maria V., Targeting emerging cancer hallmarks by transition metal complexes: Epigenetic reprogramming and epitherapies. Part II, Coordination Chemistry Reviews, 475, 2023. Crossref